High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases.
bone metastasis
epidermal growth factor receptor
non-small cell lung cancer
skeletal related events
tyrosine kinase inhibitors
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
20
08
2020
accepted:
19
10
2020
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
8
12
2020
Statut:
epublish
Résumé
The prevalence of Skeletal Related Adverse Events (SREs) in EGFR mutated non-small cell lung cancer (NSCLC) patients with bone metastases, treated with modern tyrosine kinase inhibitors (TKIs), has been scarcely investigated. We retrospectively evaluated the data of EGFR mutated NSCLC patients with bone metastases treated with TKIs in 12 Italian centers from 2014 to 2019, with the primary aim to explore type and frequency of SREs. Seventy-seven out of 274 patients enrolled (28%) developed at least one major SRE: 55/274 (20%) bone fractures, 30/274 (11%) spinal cord compression, 5/274 (2%) hypercalcemia. Median time to the onset of SRE was 3.63 months. Nine patients (3%) underwent bone surgery and 150 (55%) radiation therapy on bone. SREs were more frequently observed within the 12 months from TKI start than afterwards (71 Bone metastatic NSCLC patients with EGFR mutated disease, treated with EGFR TKIs, have a relatively long survival expectancy and are at high risk to develop SREs. The early SRE occurrence after the TKI start provides the rationale to administer bone resorption inhibitors.
Identifiants
pubmed: 33282740
doi: 10.3389/fonc.2020.588862
pmc: PMC7689017
doi:
Types de publication
Journal Article
Langues
eng
Pagination
588862Informations de copyright
Copyright © 2020 Laganà, Gurizzan, Roca, Cortinovis, Signorelli, Pagani, Bettini, Bonomi, Rinaldi, Berardi, Filetti, Giusti, Pilotto, Milella, Intagliata, Baggi, Cortellini, Soto Parra, Brighenti, Petrelli, Bennati, Bidoli, Garassino and Berruti.
Références
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
J Urol. 2002 Sep;168(3):1005-7
pubmed: 12187209
N Engl J Med. 2018 Jan 11;378(2):192-193
pubmed: 29320658
Osaka City Med J. 2013 Jun;59(1):45-52
pubmed: 23909080
BMC Cancer. 2019 Apr 3;19(1):303
pubmed: 30943924
J Thorac Oncol. 2012 Dec;7(12):1823-1829
pubmed: 23154554
Lancet Oncol. 2014 Feb;15(2):213-22
pubmed: 24439929
Cell Death Differ. 2018 Jun;25(6):1094-1106
pubmed: 29445126
Oncotarget. 2017 Jun 28;8(46):81369-81376
pubmed: 29113396
Oncol Lett. 2019 Nov;18(5):5437-5447
pubmed: 31612052
Cancer. 2004 Jun 15;100(12):2613-21
pubmed: 15197804
Eur J Endocrinol. 2019 May 1;180(5):311-320
pubmed: 30970324
Cancer Lett. 2014 Oct 10;353(1):8-16
pubmed: 25042867
Ann Oncol. 2015 Apr;26(4):779-786
pubmed: 25623049
N Engl J Med. 2018 Mar 29;378(13):1259-1261
pubmed: 29601261
Sci Rep. 2017 Feb 17;7:42979
pubmed: 28211502
Lung Cancer. 2014 Apr;84(1):86-91
pubmed: 24529684
PLoS One. 2019 Mar 20;14(3):e0213934
pubmed: 30893350
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Can Urol Assoc J. 2015 Jul-Aug;9(7-8):263-7
pubmed: 26316911
Expert Opin Ther Targets. 2016 Aug;20(8):999-1015
pubmed: 26882052
J Clin Oncol. 2011 Mar 20;29(9):1125-32
pubmed: 21343556
FASEB J. 2019 Oct;33(10):11137-11147
pubmed: 31298955
Sci Rep. 2015 Dec 22;5:18670
pubmed: 26690845
Cancer Lett. 2009 Jun 8;278(1):17-26
pubmed: 19233551
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Oncotarget. 2016 Oct 11;7(41):66480-66490
pubmed: 26624882
Lung Cancer. 2015 Aug;89(2):197-202
pubmed: 26003503
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711